Xiangqun Song

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Deng‐Yn Lin et al. · Journal of Clinical Oncology · 2013 · 762 citations · Full text

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer

Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al. · Journal of Clinical Oncology · 2015 · 381 citations · Full text

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

Li Zhang, Shenglin Ma, Xiangqun Song et al. · The Lancet Oncology · 2012 · 225 citations

Medicine, Clinical Trials, Maintenance Therapy +9

Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer

Dae Ho Lee, Jung Shin Lee, Sang‐We Kim et al. · European Journal of Cancer · 2013 · 78 citations

Second-line Treatment, Medicine, Pharmacology +7

Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial

Zhihuang Hu, Ying Cheng, Hongyu Zhang et al. · Supportive Care in Cancer · 2013 · 44 citations

Aprepitant Triple Therapy, Oncology, Medicine +6